In June 2026, the Federal Trade Commission sued Amare Global Holdings over its supplement advertising. The complaint alleged the company told buyers its products would lower cortisol, normalize serotonin, dopamine and GABA, and treat or cure depression, anxiety and ADHD in both children and adults. Every one of those statements is a testable assertion about brain chemistry. The agency’s position was that none of them had support behind it.
Cortisol, serotonin and “calm” appear across the CBD category’s marketing, usually written by people who believe neurochemical framing is safer than naming a condition. The complaint treats that framing as the claim itself.
The Evidence Base for Mood Claims
Preclinical work and a handful of clinical studies suggest cannabidiol may affect anxiety in some patients. Reviewers in the field have been consistent that the clinical evidence is not yet robust enough to establish how it should be used.
The most-cited positive result comes from a phase 2 open-label trial in which anxiety scores fell by week 4 relative to baseline, with most participants responding as early as week 1. The product was well tolerated, and the reported side effects were sleepiness, fatigue and dry mouth. Those are real findings.
They are also open-label findings, which means participants knew what they were taking. In a condition as responsive to expectation as anxiety, that design cannot separate the compound from the belief. Systematic reviews of randomized trials in this area point to the same limitations repeatedly, which are the small number of trials, inconsistent dosing across them, and treatment periods too short to say anything about sustained use.
The expectation problem has a commercial edge as well as a scientific one. Outcomes strongly shaped by belief also respond to disappointment, so customers promised a felt result but denied one reach for refunds faster. Overclaiming buys the first order and finances the dispute that follows.
Marketing departments can work with this. What they cannot do is convert “may affect anxiety in some patients under study conditions” into “clinically proven to reduce anxiety” and expect the gap to go unnoticed.
Targeting, Data, and the BetterHelp Standard
Claim substantiation is only half the exposure. In 2023 the FTC required BetterHelp to pay $7.8 million over its handling of consumer health information, which the company had disclosed to advertising platforms for targeting purposes. The agency’s director framed the case around the moment of contact, noting that someone reaching out about mental health does so in a state of vulnerability and with an expectation of privacy.
That case concerned counseling. The principle extends to brands collecting mental-health signals, including symptom-based quizzes, browsing segments, tagged lists, and lookalike audiences.
The compliance test is short. Would the customer be surprised to learn this segment exists? If the answer is yes, the segment is a liability regardless of how well it converts.
Mood Marketing at the Bank
Marketing that edges into psychiatric territory raises a brand’s risk score before any regulator sees it. Reviewers handling cbd payment applications read the same landing pages a plaintiff’s lawyer would. Copy naming a diagnosis moves an application into a slower queue.
None of that is discretionary at the bank. Categories already priced for regulatory uncertainty get priced again when the marketing invites a class action.
Vulnerable Audiences and the Reasonable Consumer
Advertising law measures a claim by what a reasonable consumer takes from it. When the audience is defined by a health condition, the standard tightens because that consumer is actively seeking relief.
This catches founders: targeting shapes claims. Recovery testimonials, mood before-and-afters, and prescription comparisons can become treatment promises. Separating media and copy decisions can make compliant copy non-compliant.
There is a duty-of-care dimension as well, separate from the legal test. Someone who postpones the treatment of anxiety because a bottle promised something is a foreseeable outcome of certain copy. Brands that would not want that outcome should not write the copy that produces it.
Compliant Language for Mood and Stress
Describe the product and the process, and stop at the diagnostic boundary. “Supports a sense of calm” describes a subjective state. “Reduces anxiety” names a condition catalogued in the DSM-5 and a product carrying that sentence has become an unapproved drug.
Anchor every claim to something the buyer can check. A stated milligram dose, a batch certificate, and a plain description of onset and duration give a customer real information and give a regulator nothing to dispute. Specificity is protective in a way that softness never is, because a number can be verified while an impression can only be argued about.
Vocabulary borrowed from clinical research carries the research’s burden with it. “Clinically studied” invites the question of which study, in whom, at what dose.
Disclosure and Duty of Care
Say what the evidence does not cover. One short line noting that research on cannabidiol and mood is early, and that anxiety disorders respond to established clinical treatment, costs nothing in conversion and demonstrates the good faith an enforcement action will look for.
Disclaimers have to be legible. Disclosure that a reasonable person would miss is treated as no disclosure at all, a principle the endorsement rules made explicit and one that applies with more force where the audience is unwell.
The two obligations reinforce each other. Copy that tells a reader what the product does not do is also copy that survives a reading by someone who was never the intended audience, which is how most regulatory attention begins.
The Limits of Technical Vocabulary
Cortisol, serotonin, dopamine and GABA are not disease names, and the FTC still called the June 2026 advertising deceptive, because the implied message was that the product corrected a brain state.
Neurochemical vocabulary offers no shelter. Claims about physiology stated in technical language raise the substantiation bar rather than lowering the risk, which is the opposite of what the vocabulary was chosen to do.
